SCHEMBL29620441

SCHEMBL29620441

O=C1c2ccncc2CN1CC(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP19 O94966 1/20 0.42
PER2 O15055 1/20 0.38
CRY2 Q49AN0 1/20 0.38
PRMT5 O14744 3/20 0.37
WDR77 Q9BQA1 3/20 0.37
CYP11B2 P19099 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
CDC25B P30305 1/20 0.34
CACNA1B Q00975 2/20 0.34
IRAK4 Q9NWZ3 2/20 0.34
KDM4E B2RXH2 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
SIRT1 Q96EB6 1/20 0.33
RIPK1 Q13546 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ADAM17 P78536 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29620429 0.87 USP19 (0.39) USP19PER2CRY2PRMT5WDR77
SCHEMBL29620451 0.80 KDM4E (0.40) USP19PER2CRY2PRMT5WDR77
SCHEMBL29620459 0.80 IDH1 (0.40) USP19PRMT5WDR77CYP11B2PDE3B
SCHEMBL29620463 0.77 KDM4E (0.43) USP19PRMT5WDR77CYP11B2PDE3B
SCHEMBL15164719 0.77 PKN2 (0.42) USP19CYP11B2PDE3BPDE3AKDM4E
SCHEMBL30947594 0.74 CYP11B2 (0.41) USP19CYP11B2MAOAMAOBPDE3B
SCHEMBL29620469 0.74 ALDH1A1 (0.49) KDM4EALOX15TSHRSIRT1NPSR1
SCHEMBL29620473 0.73 ALOX15 (0.36) USP19PRMT5WDR77CYP11B2MAOA
SCHEMBL1028252 0.73 PER2 (0.43) USP19PER2CRY2MAOAMAOB
SCHEMBL1027654 0.73 PRMT5 (0.46) PER2CRY2PRMT5WDR77ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041732-A1 ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) 2022-08-17 EP claimed
CN-114555597-A Isocitrate Dehydrogenase (IDH) inhibitors 浙江迈同生物医药有限公司 2022-05-27 CN claimed
US-12441725-B2 ISO-citrate dehydrogenase (IDH) inhibitor ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) 2025-10-14 US disclosed
US-20240116917-A1 ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) 2024-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116917-A1 ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR IDH2, IDH3A, IDH1 USP19 2560/4885PER2 2436/4885CRY2 3048/4885
US-12441725-B2 ISO-citrate dehydrogenase (IDH) inhibitor IDH2, IDH3A, IDH1 USP19 2560/4885PER2 2436/4885CRY2 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.